FDA Cites Chinese Firm for GMP Noncompliance
This article was originally published in PharmAsia News
Executive Summary
FDA has cited a Chinese firm, Kunshan Chemical and Pharmaceutical Company located in Kunshan City. Jiangsu Province, in a Sept. 6 warning letter for "significant deviations" in GMPs related to the manufacture of active pharmaceutical ingredients (APIs)
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)